Related references
Note: Only part of the references are listed.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
Amy P. Abernethy et al.
PLOS ONE (2017)
Cost-effectiveness thresholds: pros and cons
Melanie Y. Bertram et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
Ron Goeree et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System
Vivien W. Chen et al.
CANCER (2014)
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
Anthony J. Hatswell et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
EXPLORING THE IMPACT OF STRUCTURAL UNCERTAINTY IN PARTITIONED SURVIVAL MODELS FOR ONCOLOGY
J. Beca et al.
VALUE IN HEALTH (2014)
THE INHERENT BIAS FROM USING PARTITIONED SURVIVAL MODELS IN ECONOMIC EVALUATION
D. Coyle et al.
VALUE IN HEALTH (2014)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
US valuation of the EQ-5D health states - Development and testing of the D1 valuation model
JW Shaw et al.
MEDICAL CARE (2005)
Share Paper
